公开(公告)号：AU2014295143A1

公开(公告)日：2016-02-11

申请号：AU2014295143

申请日：2014-07-22

Applicant: BASF SE

Inventor： HAFNER ANDREAS ,  BLATTER FRITZ ,  SZELAGIEWICZ MARTIN ,  SIEBENHAAR BERND ,  CHIODO TIZIANA ,  HINTERMANN TOBIAS ,  SALVADOR BEATE ,  VOSSEN MARCUS

IPC: C07D417/12

Abstract: The present invention primarily relates to salts of Dasatinib, wherein the salts are in amorphous form. The salts described herein preferably comprise a cation of a compound of formula 1 and an anion of a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin. The invention is further related to pharmaceutical compositions comprising such a salt. Furthermore, the invention relates to processes for preparing said salts. The invention also relates to several aspects of using said salt or pharmaceutical composition to treat a disease.

公开(公告)号：AU2013276138A1

公开(公告)日：2015-01-22

申请号：AU2013276138

申请日：2013-06-13

Applicant: BASF SE

Inventor： CHIODO TIZIANA ,  HAFNER ANDREAS ,  HINTERMANN TOBIAS ,  SALVADOR BEATE ,  SZELAGIEWICZ MARTIN ,  BLATTER FRITZ ,  SIEBENHAAR BERND ,  VOSSEN MARCUS

IPC: C07D417/12 ,  A61K31/506 ,  A61P35/00

Abstract: The present invention refers to a multicomponent crystalline system (co-crystal) comprising a compound of formula 1 (INN: Dasatinib) and a second compound selected from methyl-4-hydroxybenzoate, or nicotinamide, or ethyl gallate, or methyl gallate, or propyl gallate, or ethyl maltol or vanillin, or men- thol, or (1R,2S,5R)-(-)-menthol,as well as to a process for obtaining the same.